Trial · NCT02390284
Stop Retinal Ganglion Cell Dysfunction Study
NCT02390284, Phase 3, Terminated, University of Miami; results first posted 2025-08-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Stop Retinal Ganglion Cell Dysfunction Study. Trials, record NCT02390284. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02390284
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Stop Retinal Ganglion Cell Dysfunction Study
- NCT number
- NCT02390284
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 28 participants, actual
- Lead sponsor
- University of Miami
- Conditions
- Glaucoma
- Interventions
- Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide
- First posted
- 2015-03-17
- Last updated
- 2025-08-26
- Results first posted
- 2025-08-26
- Limitations and caveats
- Early termination leading to small numbers of subjects analyzed and qualifying for the study.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Retinal Nerve Fiber Layer Thickness | Baseline | As measured by Optical Coherence Tomography in different timepoints as an absolute value in micrometers. |
| Secondary | Pattern Electroretinogram Amplitude | Baseline | Assessed via Pattern Electroretinogram in nanovolts |
| Secondary | Pattern Electroretinogram Phase | Baseline | Assessed via Pattern Electroretinogram in degrees |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Retinal Nerve Fiber Layer Thickness | Baseline | No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint, only baseline measurements could be included. | micrometers | MEAN |
| SECONDARY | Pattern Electroretinogram Amplitude | Baseline | No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint, only baseline measurements could be included. | nanovolts | MEAN |
| SECONDARY | Pattern Electroretinogram Phase | Baseline | No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint, only baseline measurements could be included. | degrees | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Retinal Nerve Fiber Layer Thickness | Normal | 79 | Full Range 76 to 89 | micrometers | |
| Pattern Electroretinogram Amplitude | Normal | 706 | Full Range 455 to 1344 | nanovolts | |
| Pattern Electroretinogram Phase | Normal | 67.34 | Full Range 22 to 96 | degrees |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Abnormal PERG Untreated | 0 | |
| Overall Study | STARTED | Abnormal PERG Treated | 0 | |
| Overall Study | STARTED | Normal | 28 | |
| Overall Study | COMPLETED | Abnormal PERG Untreated | 0 | |
| Overall Study | COMPLETED | Abnormal PERG Treated | 0 | |
| Overall Study | COMPLETED | Normal | 19 | |
| Overall Study | NOT COMPLETED | Abnormal PERG Untreated | 0 | |
| Overall Study | NOT COMPLETED | Abnormal PERG Treated | 0 | |
| Overall Study | NOT COMPLETED | Normal | 9 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Abnormal PERG Untreated | 0 | 0 |
| Total, all-cause mortality | Abnormal PERG Treated | 0 | 0 |
| Total, all-cause mortality | Normal | 0 | 28 |
| Total, other adverse events | Abnormal PERG Untreated | 0 | 0 |
| Total, other adverse events | Abnormal PERG Treated | 0 | 0 |
| Total, other adverse events | Normal | 0 | 28 |
| Total, serious adverse events | Abnormal PERG Untreated | 0 | 0 |
| Total, serious adverse events | Abnormal PERG Treated | 0 | 0 |
| Total, serious adverse events | Normal | 0 | 28 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01EY014957 | Reversible Dysfunction of Retinal Ganglion Cells in Glaucoma | PORCIATTI, VITTORIO | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE | NATIONAL EYE INSTITUTE | 2005 to 2017 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02390284
GET https://conductscience.org/api/trials/v1/NCT02390284/registered